Marshall Wace LLP Grows Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Marshall Wace LLP raised its position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 332.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 264,523 shares of the company's stock after purchasing an additional 203,361 shares during the quarter. Marshall Wace LLP owned 0.63% of SI-BONE worth $3,709,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in SIBN. Jane Street Group LLC grew its stake in shares of SI-BONE by 29.0% during the 3rd quarter. Jane Street Group LLC now owns 77,359 shares of the company's stock valued at $1,081,000 after purchasing an additional 17,410 shares during the period. Barclays PLC grew its stake in shares of SI-BONE by 190.8% during the 3rd quarter. Barclays PLC now owns 96,623 shares of the company's stock valued at $1,350,000 after purchasing an additional 63,402 shares during the period. Geode Capital Management LLC grew its stake in shares of SI-BONE by 3.4% during the 3rd quarter. Geode Capital Management LLC now owns 924,044 shares of the company's stock valued at $12,921,000 after purchasing an additional 30,005 shares during the period. Franklin Resources Inc. grew its stake in shares of SI-BONE by 9.4% during the 3rd quarter. Franklin Resources Inc. now owns 20,220 shares of the company's stock valued at $265,000 after purchasing an additional 1,745 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of SI-BONE by 14.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company's stock valued at $2,486,000 after purchasing an additional 22,732 shares during the period. 98.11% of the stock is currently owned by institutional investors.

SI-BONE Price Performance

SIBN stock traded up $0.06 during midday trading on Monday, hitting $14.47. The company's stock had a trading volume of 277,689 shares, compared to its average volume of 360,732. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.16. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $614.29 million, a price-to-earnings ratio of -15.73 and a beta of 1.02. The company has a 50 day moving average of $14.93 and a two-hundred day moving average of $14.66.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. The firm had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, analysts expect that SI-BONE, Inc. will post -0.78 EPS for the current year.

Insider Activity

In related news, insider Anthony J. Recupero sold 3,311 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total transaction of $46,850.65. Following the sale, the insider now owns 284,555 shares in the company, valued at approximately $4,026,453.25. This represents a 1.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the sale, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. The trade was a 1.26 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,776 shares of company stock worth $96,644. 3.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

SIBN has been the subject of a number of recent research reports. Truist Financial reiterated a "buy" rating and set a $22.00 price objective (up from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Needham & Company LLC boosted their price objective on SI-BONE from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $24.40.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.